GlycoMimetics Inc reports results for the quarter ended March 31 - Earnings Summary
16/05/2025 23:43
GlycoMimetics Inc GLYC.OQ reported a quarterly adjusted loss of 4 cents per share for the quarter ended March 31, higher than the same quarter last year, when the company reported EPS of -17 cents. The lone analyst forecast for the quarter was for a loss of 5 cents per share. Reported revenue was zero; analysts expected zero. GlycoMimetics Inc's reported EPS for the quarter was a loss of 4 cents. The company reported a quarterly loss of $2.34 million. GlycoMimetics Inc shares had risen by 19.0% this quarter and gained 0.3% so far this year. FORECAST CHANGES In the last 30 days, there have been no earnings estimate revisions by analysts covering the company. RECOMMENDATIONS The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 1 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy" This summary was machine generated from LSEG data May 16 at 10:43 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
| QUARTER ENDING | ESTIMATE | ACTUAL | BEAT, MET, MISSED |
| Mar. 31 2025 | -0.05 | -0.04 | Beat |
| -0.11 | |||
| -0.26 | |||
| Jun. 30 2024 | -0.17 | -0.16 | Beat |
Recent news on Crescent Biopharma
See all newsBrief: Crescent Biopharma - Potential To Initiate First CR-001 Phase 3 Study In Early 2028
Brief: Crescent Biopharma Announces FDA Clearance Of Ind Application For CR-002, A Pd-L1-Targeted Topoisomerase Inhibitor Adc, For The Treatment Of Solid Tumors
Crescent Biopharma posts smaller-than-expected Q2 net loss
U.S. STOCKS ON THE MOVE-Cintas, Veradermics
Crescent Biopharma slips on $125 mln share offering